Harmony Biosciences Holdings, Inc.
HRMYNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $868.5M | $714.7M | $582.0M | $437.9M | $305.4M | $159.7M |
| Operating income | $208.5M | $190.8M | $192.0M | $120.2M | $87.5M | $17.0M |
| Net income | $158.7M | $145.5M | $128.9M | $181.5M | $34.6M | −$36.9M |
| Total assets | $1.27B | $999.2M | $811.4M | $673.9M | $433.4M | $427.1M |
| Total liabilities | $401.4M | $340.0M | $344.5M | $271.0M | $246.9M | $329.9M |
| Equity | $870.2M | $659.2M | $467.0M | $402.8M | $186.5M | $97.2M |
| EPS (diluted) | $2.71 | $2.51 | $2.13 | $2.97 | $0.58 | $-2.48 |
| Shares out. | 57.3M | 56.8M | 59.6M | 58.9M | 56.9M | 56.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 24.0%
- Net margin
- 18.3%
- Return on equity
- 18.2%
- Return on assets
- 12.5%
- Return on capital (ROCE)
- 20.4%
- Liabilities / assets
- 31.6%
- Debt / equity
- 0.46×
- Book value / share
- $15.17
- Revenue growth (YoY)
- 21.5%
- Net income growth (YoY)
- 9.1%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 7.17safe
- Accruals / assets
- −14.9%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 7 good- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2026-07A Study of Pitolisant in Patients With Prader-Willi Syndrome
- Phase 3Recruitingreadout ~2027-10A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Idiopathic Hypersomnia (IH)
- Phase 3Enrolling By Invitationreadout ~2030-08A Study of Pitolisant in Participants With Prader-Willi Syndrome
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Mar 27, 2026
- Fmr LlcPassive (13G)Feb 5, 2026
- Valor Iv Pharma Holdings, LlcPassive (13G)Nov 14, 2025
- Blackrock, Inc.Passive (13G)Apr 29, 2025
- Marshman Fund Trust IiPassive (13G)Feb 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6.6M | 8.2 | -4.1% |
| Apr 30, 2026 | 6.9M | 6.4 | -5.3% |
| Apr 15, 2026 | 7.3M | 11.9 | -4.7% |
| Mar 31, 2026 | 7.6M | 10.5 | +0.3% |
| Mar 13, 2026 | 7.6M | 10.8 | -4.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 14, 2026
- Results of operations · Regulation FD disclosureMay 7, 2026
- Director / officer change · Regulation FD disclosureApr 14, 2026
- Director / officer change · Regulation FD disclosureApr 2, 2026
- Results of operations · Regulation FD disclosureFeb 24, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Results of operations · Regulation FD disclosureNov 4, 2025
- Results of operationsOct 23, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.